All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

histrelin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
pituitary hormone-release stimulating peptides	2975	76712-82-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: vantas Luteinizing hormone-releasing factor (pig) histrelin acetate histrelin	gonadotropin releasing hormone agonist Molecular weight: 1323.53 Formula: C66H86N18O12 CLOGP: -4.08 LIPINSKI: 3 HAC: 30 HDO: 16 TPSA: 446.86 ALOGS: -4.73 ROTB: 34

Drug dosage:

Dose	Unit	Route
0.14	mg	implant

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
Dec. 24, 1991	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Incorrect product administration duration	285.09	66.93	56	568	19266	90608557
Procedural complication	237.19	66.93	40	584	5838	90621985
Device breakage	214.64	66.93	42	582	14002	90613821
Implant site rash	173.99	66.93	20	604	161	90627662

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Incorrect product administration duration	121.23	60.90	21	164	5859	42615291
Device breakage	109.56	60.90	18	167	3631	42617519
Procedural complication	72.83	60.90	13	172	4206	42616944
Delayed puberty	64.05	60.90	8	177	223	42620927

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Incorrect product administration duration	213.75	58.64	42	494	20456	110568307
Device breakage	179.10	58.64	34	502	13735	110575028
Implant site rash	162.48	58.64	18	518	149	110588614
Procedural complication	162.31	58.64	29	507	8376	110580387
Device expulsion	78.42	58.64	20	516	30871	110557892
Implant site infection	65.95	58.64	11	525	2092	110586671

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L02AE05	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ENDOCRINE THERAPY HORMONES AND RELATED AGENTS Gonadotropin releasing hormone analogues
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:63533	gonadotropin releasing hormone agonist
FDA MoA	N0000175654	Gonadotropin Releasing Hormone Receptor Agonists
FDA EPC	N0000175655	Gonadotropin Releasing Hormone Receptor Agonist

Related Drugs by ATC class:

L02AE Gonadotropin releasing hormone analogues 5 drugs

bicalutamidebuserelingoserelinleuprorelintriptorelin

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Precocious puberty	indication	400179000
Advanced Prostatic Carcinoma	indication
Hypercholesterolemia	contraindication	13644009
Hypertensive disorder	contraindication	38341003	DOID:10763
Diabetes mellitus	contraindication	73211009	DOID:9351
Hyperglycemia	contraindication	80394007	DOID:4195
Pregnancy, function	contraindication	289908002
Cardiovascular event risk	contraindication	395112001
Breastfeeding (mother)	contraindication	413712001
Obesity	contraindication	414916001	DOID:9970
Smokes tobacco daily	contraindication	449868002
Vertebral Metastases	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.65	acidic
pKa2	11.9	acidic
pKa3	12.79	acidic
pKa4	12.97	acidic
pKa5	13.16	acidic
pKa6	13.43	acidic
pKa7	13.89	acidic
pKa8	10.75	Basic
pKa9	7.01	Basic
pKa10	6.41	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
50MG	SUPPRELIN LA	ENDO OPERATIONS	N022058	May 3, 2007	RX	IMPLANT	SUBCUTANEOUS	8062652	June 16, 2026	METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Gonadotropin-releasing hormone receptor	GPCR	P30968	GNRHR_HUMAN	AGONIST				CHEMBL	CHEMBL

External reference:

ID	Source
D02369	KEGG_DRUG
220810-26-4	SECONDARY_CAS_RN
4025439	VANDF
4025440	VANDF
4025500	VANDF
CHEBI:5739	CHEBI
CHEMBL1201255	ChEMBL_ID
CHEMBL1200509	ChEMBL_ID
C029256	MESH_SUPPLEMENTAL_RECORD_UI
3884	IUPHAR_LIGAND_ID
DB06788	DRUGBANK_ID
H50H3S3W74	UNII
1294622	RXNORM
4829	MMSL
60923	MMSL
d00575	MMSL
004142	NDDF
004143	NDDF
008318	NDDF
008319	NDDF
109049002	SNOMEDCT_US
109050002	SNOMEDCT_US
126198004	SNOMEDCT_US
C0121902	UMLSCUI
5733	INN_ID
25077993	PUBCHEM_CID
H50H3S3W74	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
SUPPRELINLA	HUMAN PRESCRIPTION DRUG LABEL	1	67979-002	IMPLANT	50 mg	SUBCUTANEOUS	NDA	25 sections